Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial. (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s129. https://doi.org/10.25251/skin.1.supp.128